{"title":"Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections","authors":"","doi":"10.1016/j.pharmthera.2024.108688","DOIUrl":null,"url":null,"abstract":"<div><p>Antibiotic-resistant bacteria are currently an important public health concern posing a serious threat due to their resistance to the current arsenal of antibiotics. Uropathogens <em>Escherichia coli (UPEC), Proteus mirabilis, Klebsiella pneumoniae</em> and <em>Enterococcus faecalis</em>, antibiotic-resistant gram-negative bacteria, cause serious cases of prolonged UTIs, increasing healthcare costs and potentially even leading to the death of an affected patient. This review discusses current knowledge about the increasing resistance to currently recommended antibiotics for UTI therapy, as well as novel therapeutic options. Traditional antibiotics are still a part of the therapy guidelines for UTIs, although they are often not effective and have serious side effects. Hence, novel drugs are being developed, such as combinations of β-lactam antibiotics with cephalosporins and carbapenems. Siderophoric cephalosporins, such as cefiderocol, have shown potential in the treatment of individuals with significant gram-negative bacterial infections, as well as aminoglycosides, fluoroquinolones and tetracyclines that are also undergoing clinical trials. The use of cranberry and probiotics is another potential curative and preventive method that has shown antimicrobial and anti-inflammatory effects. However, further studies are needed to assess the efficacy and safety of probiotics containing cranberry extract for UTI prevention and treatment. An emerging novel approach for UTI treatment is the use of immuno-prophylactic vaccines, as well as different nanotechnology solutions such as nanoparticles (NP). NP have the potential to be used as delivery systems for drugs to specific targets. Furthermore, nanotechnology could enable the development of nano antibiotics with improved features by the application of different NPs in their structure, such as gold and copper NPs. However, further high-quality research is required for the synthesis and testing of these novel molecules, such as safety evaluation and pharmacovigilance.</p></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":"261 ","pages":"Article 108688"},"PeriodicalIF":12.0000,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163725824001086/pdfft?md5=04c16e2d669acf095ccda39eb8fb74ad&pid=1-s2.0-S0163725824001086-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0163725824001086","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Antibiotic-resistant bacteria are currently an important public health concern posing a serious threat due to their resistance to the current arsenal of antibiotics. Uropathogens Escherichia coli (UPEC), Proteus mirabilis, Klebsiella pneumoniae and Enterococcus faecalis, antibiotic-resistant gram-negative bacteria, cause serious cases of prolonged UTIs, increasing healthcare costs and potentially even leading to the death of an affected patient. This review discusses current knowledge about the increasing resistance to currently recommended antibiotics for UTI therapy, as well as novel therapeutic options. Traditional antibiotics are still a part of the therapy guidelines for UTIs, although they are often not effective and have serious side effects. Hence, novel drugs are being developed, such as combinations of β-lactam antibiotics with cephalosporins and carbapenems. Siderophoric cephalosporins, such as cefiderocol, have shown potential in the treatment of individuals with significant gram-negative bacterial infections, as well as aminoglycosides, fluoroquinolones and tetracyclines that are also undergoing clinical trials. The use of cranberry and probiotics is another potential curative and preventive method that has shown antimicrobial and anti-inflammatory effects. However, further studies are needed to assess the efficacy and safety of probiotics containing cranberry extract for UTI prevention and treatment. An emerging novel approach for UTI treatment is the use of immuno-prophylactic vaccines, as well as different nanotechnology solutions such as nanoparticles (NP). NP have the potential to be used as delivery systems for drugs to specific targets. Furthermore, nanotechnology could enable the development of nano antibiotics with improved features by the application of different NPs in their structure, such as gold and copper NPs. However, further high-quality research is required for the synthesis and testing of these novel molecules, such as safety evaluation and pharmacovigilance.
抗生素耐药细菌是当前公共卫生的一个重要问题,由于它们对现有抗生素库产生耐药性,因此构成了严重威胁。尿路病原菌大肠埃希菌(UPEC)、奇异变形杆菌、肺炎克雷伯菌和粪肠球菌是耐抗生素革兰氏阴性菌,它们会导致严重的长期UTI病例,增加医疗成本,甚至可能导致患者死亡。这篇综述讨论了有关目前推荐用于治疗尿毒症的抗生素耐药性不断增加的现有知识,以及新的治疗方案。传统抗生素仍然是尿毒症治疗指南的一部分,尽管它们往往效果不佳且有严重的副作用。因此,人们正在开发新型药物,如β-内酰胺类抗生素与头孢菌素和碳青霉烯类的复方制剂。嗜苷头孢菌素(如头孢克洛)已显示出治疗严重革兰氏阴性菌感染患者的潜力,氨基糖苷类、氟喹诺酮类和四环素类药物也正在进行临床试验。使用蔓越莓和益生菌是另一种潜在的治疗和预防方法,已显示出抗菌和消炎作用。然而,还需要进一步的研究来评估含有蔓越莓提取物的益生菌在预防和治疗 UTI 方面的有效性和安全性。一种新出现的治疗尿毒症的新方法是使用免疫预防疫苗以及不同的纳米技术解决方案,如纳米颗粒(Nanoparticles)。纳米颗粒有可能被用作向特定靶点输送药物的系统。此外,通过在纳米抗生素的结构中应用不同的纳米粒子(如金和铜纳米粒子),纳米技术还能开发出功能更强的纳米抗生素。不过,这些新型分子的合成和测试,如安全性评估和药物警戒,还需要进一步的高质量研究。
期刊介绍:
Pharmacology & Therapeutics, in its 20th year, delivers lucid, critical, and authoritative reviews on current pharmacological topics.Articles, commissioned by the editor, follow specific author instructions.This journal maintains its scientific excellence and ranks among the top 10 most cited journals in pharmacology.